Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822952 · ClinicalTrials.gov registry record
Prostate Mechanical Imager (PMI) Clinical Bridging Study
A clinical trial of Prostatic Neoplasms and Prostatic Hyperplasia, sponsored by Artann Laboratories.
- Completed
- Registry status
- 71
- Enrollment target
- 5
- Study locations
NCT00822952 is a study of Prostatic Neoplasms and Prostatic Hyperplasia that has completed, run by Artann Laboratories. The registered enrollment target is 71 participants, below the 513-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00822952, a study of Prostatic Neoplasms and Prostatic Hyperplasia, has completed, sponsored by Artann Laboratories.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite elasticity images of the prostate.
Conditions Studied
Study Locations (5)
Minnesota
- University of Minnesota/VA Medical Center - Minneapolis
- Mayo Clinic - Rochester
New Jersey
- Robert Wood Johnson Medical Center - New Brunswick
New York
- AccuMed Research Associates - Garden City
Pennsylvania
- Urology Associates of Lancaster - Lancaster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00822952
The ClinicalTrials.gov registry entry for NCT00822952 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 513-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (86% lower). The listed sponsor is Artann Laboratories, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostatic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT00822952 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT00822952 about?
NCT00822952 is a clinical study titled "Prostate Mechanical Imager (PMI) Clinical Bridging Study". The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite elasticity images of the prostate.
What is the current status of trial NCT00822952?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2008-10. Estimated completion is 2009-09.
What conditions does trial NCT00822952 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Prostatic Hyperplasia.
Who is sponsoring clinical trial NCT00822952?
This trial is sponsored by Artann Laboratories, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00822952 being conducted?
This trial has 5 study locations across Minnesota, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RECRUITING
-
Men at High Genetic Risk for Prostate Cancer
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.